China Pharma Holdings Enters Material Definitive Agreement
Ticker: CPHI · Form: 8-K · Filed: Dec 13, 2024 · CIK: 1106644
| Field | Detail |
|---|---|
| Company | China Pharma Holdings, Inc. (CPHI) |
| Form Type | 8-K |
| Filed Date | Dec 13, 2024 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 5 min |
| Key Dollar Amounts | $0.001, $600,000, $0 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, corporate-actions
TL;DR
China Pharma Holdings (CPHI) signed a material definitive agreement on Dec 12, 2024.
AI Summary
On December 12, 2024, China Pharma Holdings, Inc. entered into a Material Definitive Agreement. The company, previously known as TS Electronics Inc. and Softstone Inc., is incorporated in Nevada and operates in the Pharmaceutical Preparations industry.
Why It Matters
This filing indicates a significant new development for China Pharma Holdings, Inc., potentially impacting its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks and opportunities that may affect the company's financial stability and market position.
Key Players & Entities
- CHINA PHARMA HOLDINGS, INC. (company) — Registrant
- TS ELECTRONICS INC (company) — Former company name
- SOFTSTONE INC (company) — Former company name
- December 12, 2024 (date) — Date of earliest event reported
FAQ
What type of material definitive agreement did China Pharma Holdings, Inc. enter into?
The filing does not specify the exact nature of the Material Definitive Agreement, only that one was entered into on December 12, 2024.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on December 12, 2024.
What is the primary business of China Pharma Holdings, Inc. according to the filing?
China Pharma Holdings, Inc. is in the Pharmaceutical Preparations industry, with SIC code 2834.
What were some of China Pharma Holdings, Inc.'s former company names?
The company was formerly known as TS ELECTRONICS INC and SOFTSTONE INC.
In which U.S. state is China Pharma Holdings, Inc. incorporated?
China Pharma Holdings, Inc. is incorporated in Nevada.
Filing Stats: 1,195 words · 5 min read · ~4 pages · Grade level 13 · Accepted 2024-12-13 08:20:08
Key Financial Figures
- $0.001 — f the Company's common stock, par value $0.001 per share (the " Common Stock "), havin
- $600,000 — ng an aggregate offering price of up to $600,000 (the " Shares ") (the " Offering ") . A
- $0 — shall the per share price be lower than $0.15, which is to be stated in the purcha
Filing Documents
- ea0224537-8k_china.htm (8-K) — 32KB
- ea022453701ex1-1_china.htm (EX-1.1) — 95KB
- ea022453701ex5-1_china.htm (EX-5.1) — 21KB
- ea022453701ex99-1_china.htm (EX-99.1) — 8KB
- 0001213900-24-108617.txt ( ) — 358KB
- cphi-20241212.xsd (EX-101.SCH) — 3KB
- cphi-20241212_lab.xml (EX-101.LAB) — 33KB
- cphi-20241212_pre.xml (EX-101.PRE) — 22KB
- ea0224537-8k_china_htm.xml (XML) — 4KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On December 12, 2024, China Pharma Holdings Inc.. (the " Company ") entered into that certain securities purchase agreement (the " SPA ") with certain institutional investor (the " Investor ") with respect to an at-the-market offering under which the Investor may purchase, and the Company may sell within the commitment period from December 12, 2024 to December 31, 2024, at the Investor's sole discretion, shares of the Company's common stock, par value $0.001 per share (the " Common Stock "), having an aggregate offering price of up to $600,000 (the " Shares ") (the " Offering ") . Any Shares offered and sold in the Offering will be issued pursuant to the Company's shelf Registration Statement on Form S-3 (File No. 333-276481) filed with the Securities and Exchange Commission (the " SEC ") on January 12, 2024, as amended, which was declared effective on February 14, 2024, the related prospectus contained therein, and the prospectus supplement relating to the Offering filed with the SEC on December 13, 2024. The Investor may acquire our Common Stock through one or more closings upon our receipt of purchase notices. The number of our Common Stock will be determined based on the at-the-market price equal to the lower of (i) the closing price the day prior to the purchase notice or (ii) the five (5) day average closing prices as reported by Bloomberg or on the NYSE American Market's website, but in no event shall the per share price be lower than $0.15, which is to be stated in the purchase notice subject to repricing adjustments as contemplated under the SPA as follows. In the event the Company's delivery of the shares is not confirmed by 1:00 pm E.T. on the trading day the purchase notice is submitted, the Investor has the right to adjust the purchase price to match the at-the-market price on the date of the delivery of the purchase notice, which is only permitted if the market price on the delivery day is lower
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Form of the Securities Purchase Agreement, dated December 12, 2024, by and between China Pharma Holdings Inc. and the Investor 5.1 Opinion of Flangas Law Group 99.1 Press Release Announcing the Entry of the At-the-Market Equity Financing 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 13, 2024 CHINA PHARMA HOLDINGS, INC. By: /s/ Zhilin Li Name: Zhilin Li Title: President and Chief Executive Officer 3